UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of November, 2023
Commission File Number: 001-41106
Incannex Healthcare Limited
(Exact name of Registrant as specified in its
charter)
not applicable
(Translation of Registrant’s name into
English)
Australia
(Jurisdiction of incorporation or organization)
Joel Latham
Chief Executive Officer and Managing Director
Level 39, Rialto South Tower
525 Collins Street
Melbourne 3000
Australia
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F:
Form 20-F ☒
Form 40-F ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM
6-K
On November 16, 2023, Incannex Healthcare Limited released the announcements
attached to this Form 6-K as Exhibit 99.1 and Exhibit 99.2.
Signatures
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
Incannex Healthcare Limited |
| |
|
|
| Date: November 16, 2023 |
By: |
/s/ Joel Latham |
| |
Name: |
Joel Latham |
| |
Title: |
Chief Executive Officer and Managing Director |
INDEX TO EXHIBITS
3
Exhibit 99.1
 |
Date: November 16, 2023
Public Announcement (NASDAQ: IXHL) (ASX: IHL) |
Not for release to US wire services or
distribution in the United States
Court Approves Schemes
Melbourne, Australia, November 16, 2023
– Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) is
pleased to advise that the Federal Court of Australia (Court) has today made orders approving the proposed schemes of arrangement
between Incannex and its shareholders and Incannex and its option holders pursuant to which it is proposed that Incannex Healthcare Inc.
(Incannex US) will become the new parent entity of the Incannex group (Schemes).
Lodgement of Court Orders
Pursuant to section 411(10) of the Corporations
Act 2001 (Cth), the Schemes will become legally effective upon lodgement of the Court orders with the Australian Securities and Investments
Commission (ASIC).
It is expected that a copy of the Court’s
orders with respect to the Schemes will be lodged with ASIC tomorrow, at which time the Schemes will become legally effective.
Incannex intends to apply for Incannex shares
to be suspended from trading on ASX, subject to the Schemes becoming legally effective, with effect from the close of trading on Friday,
17 November 2023.
Indicative Timetable
The key indicative dates and times for the Schemes
are as follows:
| Effective date of the Schemes |
17 November 2023 |
| |
|
| Last date of trading of Incannex shares on ASX |
17 November 2023 |
| |
|
| Record date for determining entitlements to the consideration under the Schemes |
7:00pm (Melbourne time) on 21 November 2023 |
| |
|
| Implementation date for the Schemes |
28 November 2023 |
| |
|
| Delisting of Incannex from the official list of ASX |
29 November 2023 |
| |
|
| Admission of Incannex US on Nasdaq |
29 November 2023 |
| |
|
| First day of trading of Incannex US shares on Nasdaq |
Expected to commence promptly following the Implementation Date |
Note: All stated dates and times are indicative only. Any changes
to the above timetable will be announced to ASX and Nasdaq and will be available on Incannex's website at https://www.incannex.com/.
Incannex Healthcare Limited (ABN: 93 096
635 246)
Level 39, Rialto South Tower, 525 Collins
Street, Melbourne VIC 3000
P: +61 409 840 786
|
Date: November 16, 2023
Public Announcement (NASDAQ: IXHL) (ASX: IHL) |
Small Parcel Holders
Shareholders who, based on their holding of Incannex
shares on the record date, hold less than a marketable parcel of Incannex shares (being a parcel of shares of less than A$500 based on
the closing price on the last day of trading on ASX prior to the record date) (Small Parcel Holders) have until 7:00pm (Melbourne
time) on the effective date to submit a Small Parcel Holder Election Form.
Further details on the consideration received
by Small Parcel Holders and the process for Small Parcel Holders to make an election is set out in section 5.5 of the Scheme Booklet.
Further Information
If you have any questions in relation to the Schemes,
please contact the Incannex Schemes Information Line on 1300 429 179 (within Australia) or +61 2 7208 4522 (outside Australia) Monday
to Friday between 8:30am and 7:00pm (Melbourne time).
This announcement
has been approved for release to ASX by the Incannex Board of Directors.
END
About Incannex Healthcare Limited
Incannex is a clinical stage pharmaceutical development
company that is developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive
sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis,
inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications.
U.S. FDA approval and registration, subject to ongoing
clinical success, is being pursued for each drug and therapy under development. Each indication under investigation currently has no,
or limited, existing registered pharmacotherapy (drug) treatments available to the public and represent major global economic opportunities
to Incannex and its shareholders.
Incannex has a strong patent filing strategy in place
as it develops its products and therapies in conjunction with its medical and scientific advisory board and partners. The Company holds
19 granted patents and 29 pending patents. Incannex is listed on the Australian Stock Exchange (ASX) with stock code “IHL”
and also has American Depository Shares listed on NASDAQ under code “IXHL”.
Website: www.incannex.com.au
Investors: investors@incannex.com.au
Incannex Healthcare Limited (ABN: 93 096
635 246)
Level 39, Rialto South Tower, 525 Collins
Street, Melbourne VIC 3000
P: +61 409 840 786
|
Date: November 16, 2023
Public Announcement (NASDAQ: IXHL) (ASX: IHL) |
Forward-looking statements
This press release contains "forward-looking
statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of
1995. These forward-looking statements are made as of the date they were first issued and were based on current expectations and estimates,
as well as the beliefs and assumptions of management. The forward-looking statements included in this press release represent Incannex's
views as of the date of this press release. Incannex anticipates that subsequent events and developments may cause its views to change.
Incannex undertakes no intention or obligation to update or revise any forward-looking statements, whether as of a result of new information,
future events or otherwise. These forward-looking statements should not be relied upon as representing Incannex's views as of any date
after the date of this press release.
Not an offer in the United States
This announcement has been prepared for publication
in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an
offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described
in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in
the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable
US state securities laws.
Contact Information
|
Incannex Healthcare Limited
Mr Joel Latham
Managing Director and Chief Executive Officer
+61 409 840 786
joel@incannex.com.au |
Investor Relations Contact – United States
Alyssa Factor
Edison Group
+1 (860) 573 9637
afactor@edisongroup.com
|
Incannex Healthcare Limited (ABN: 93 096
635 246)
Level 39, Rialto South Tower, 525 Collins
Street, Melbourne VIC 3000
P: +61 409 840 786
Page 3 | 3
Exhibit
99.2
 |
Date: November 16, 2023
Public Announcement (NASDAQ: IXHL) (ASX: IHL) |
FEDERAL COURT OF AUSTRALIA
APPROVES INCANNEX’S RE-DOMICILIATION AND LODGEMENT OF COURT ORDERS WITH ASIC
Melbourne, November 16, 2023 Incannex Healthcare
Limited (ASX: IHL) (NASDAQ: IXHL) (the “Company” or “Incannex”) is pleased to announce that the
Federal Court of Australia (“Court”) has today made orders approving the scheme of arrangement in relation to the Company’s
proposed re-domiciliation from Australia to the United States (“Scheme”), under which Incannex Healthcare Inc. (“Holdco”)
will become the ultimate parent company of Incannex Healthcare Limited following the implementation of the Scheme.
It is expected that a copy of the Court’s
orders with respect to the Schemes will be lodged with ASIC tomorrow, at which time the Schemes will become legally effective.
Incannex has applied to ASX to suspend quotation and trading of Incannex shares, with effect from the close of trading on ASX on
November 17, 2023. Incannex’s ADRs, however, will continue to trade on Nasdaq until the implementation date
(November 28, 2023).
Incannex shareholders and optionholders who hold shares
and options on the record date for the Scheme (7:00pm (Melbourne time) on Tuesday, November 21, 2023) will be entitled to receive
the Scheme consideration (in accordance with the terms of the Scheme as set out in Section 5.2 and 5.3 of the Scheme Booklet dated
October 4, 2023 (“Scheme Booklet”)). The Scheme consideration will be paid to Scheme Shareholders and Scheme
Optionholders (as defined in the Scheme Booklet) on the implementation date.
END
About Incannex Healthcare Limited
Incannex is a clinical stage pharmaceutical development
company that is developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive
sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis,
inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications.
U.S. FDA approval and registration, subject to ongoing
clinical success, is being pursued for each drug and therapy under development. Each indication under investigation currently has no,
or limited, existing registered pharmacotherapy (drug) treatments available to the public and represent major global economic opportunities
to Incannex and its shareholders.
Incannex has a strong patent filing strategy in place
as it develops its products and therapies in conjunction with its medical and scientific advisory board and partners. The Company holds
19 granted patents and 29 pending patents. Incannex is listed on the Australian Stock Exchange (ASX) with stock code “IHL”
and also has American Depository Shares listed on NASDAQ under code “IXHL”.
Website: www.incannex.com.au
Investors: investors@incannex.com.au
Forward-looking statements
This press release contains "forward-looking
statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of
1995. These forward-looking statements are made as of the date they were first issued and were based on current expectations and estimates,
as well as the beliefs and assumptions of management. The forward-looking statements included in this press release represent Incannex's
views as of the date of this press release. Incannex anticipates that subsequent events and developments may cause its views to change.
Incannex undertakes no intention or obligation to update or revise any forward-looking statements, whether as of a result of new information,
future events or otherwise. These forward-looking statements should not be relied upon as representing Incannex's views as of any date
after the date of this press release.
Incannex Healthcare Limited (ABN: 93 096
635 246)
Level 39, Rialto South Tower, 525 Collins
Street, Melbourne VIC 3000
P: +61 409 840 786
|
Date: November 16, 2023
Public Announcement (NASDAQ: IXHL) (ASX: IHL) |
Important Notice
This press release does not constitute an offer to
sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this
press release have not been registered under the US Securities Act of 1933, as amended, and may not be offered or sold in the United States
except in transactions exempt from, or not subject to, registration under the US Securities Act and applicable US state securities laws.
Contact Information
|
Incannex Healthcare Limited
Mr Joel Latham
Managing Director and Chief Executive Officer
+61 409 840 786
joel@incannex.com.au |
Investor Relations Contact – United States
Alyssa Factor
Edison Group
+1 (860) 573 9637
afactor@edisongroup.com
|
Incannex Healthcare Limited (ABN: 93 096
635 246)
Level 39, Rialto South Tower, 525 Collins
Street, Melbourne VIC 3000
P: +61 409 840 786
Page 2 | 2
Incannex Healthcare (NASDAQ:IXHL)
Historical Stock Chart
From Apr 2024 to May 2024
Incannex Healthcare (NASDAQ:IXHL)
Historical Stock Chart
From May 2023 to May 2024
